Table 1.
Subject baseline characteristics.
| RF (n=41, NO=21) | DM (n=11, NO=10) | PAD (n=29, NO=10) | DM+PAD (n=9, NO=9) | |
|---|---|---|---|---|
| Age (yr) | 53.5±1.1* | 61.2±1.7 | 67.2±2.1 | 62.9±3.8 |
| Ht (cm) | 168.9±2.0 | 175.8±2.5 | 172.1±2.5 | 175.4±3.9 |
| Wt (kg) | 80.2±3.2 | 97.0±3.2 | 77.9±3.4 | 83.5±4.9 |
| BMI | 28.58 | 32.17 | 27.87 | 28.84 |
| SBP (mmHg) | 129.8±3.3* | 151.9±6.7 | 155.5±3.7 | 162.6±6.1 |
| DBP (mmHg) | 80.9±1.5 | 81.3±3.1 | 79.2±1.9 | 80.4±2.3 |
| ABI | 1.05±0.02† | 1.08±0.11† | 0.63±0.21 | 0.72±0.13 |
| CAD (%) | 0† | 0† | 41 | 33 |
| CVA (%) | 0 | 0 | 22* | 0 |
| CHF (%) | 0 | 0 | 13* | 0 |
| Smoking % | ||||
| Never | 74† | 55† | 22 | 22 |
| Former | 19 | 45 | 47 | 44 |
| Current | 7 | 0† | 31 | 34 |
| Medications % | ||||
| Ace Inhibitor | 2* | 64 | 41 | 67 |
| Beta Blocker | 0* | 36 | 41 | 44 |
| Statin | 12† | 36† | 72 | 56 |
| Aspirin | 26† | 55 | 69 | 100* |
| Insulin | 0 | 0 | 0 | 33* |
| Metformin | 0§ | 90 | 0§ | 44 |
| Glipizide | 0§ | 9 | 0§ | 11 |
| Glucapharge | 0 | 0 | 0 | 11 |
| Actos | 0 | 18* | 0 | 0 |
| Avandia | 0 | 18* | 0 | 0 |
| Glucotrol | 0 | 18* | 0 | 0 |
| Novolin | 0 | 9 | 0 | 0 |
| Glimepiride | 0 | 9 | 0 | 0 |
| Brach Diam (mm) | 3.16±0.11 | 3.42±0.22 | 3.27±0.11 | 3.63±0.28 |
| Plasma NO2- (nM) | 93.8±12.5 | 79.0±8.8 | 112±19.8 | 77.6±13.1 |
| Plasma NO3- (μM) | 14.2±1.6# | 40.6±5.4 | 25.7±4.3 | 26.8.6±6.0 |
*
= significantly different than other groups (p≤0.05)
†
= significantly different than PAD, DM+PAD group (p≤0.05)
#
= significantly different than DM group (p≤0.05)
§
= significantly different from DM, DM+PAD group (p≤0.05)
CVA = Cerebrovascular disease, CHF = Congestive Heart Failure